来源：新浪证券-红岸工作室 2月27日，中红医疗涨1.40%，成交额3445.07万元，换手率0.68%，总市值55.75亿元。 异动分析 智能医疗+医疗器械概念+宠物经济+人民币贬值受益+国企改革 区间今日近3日近5日近10日近20日主力净流入-2.87万-969.67万-1403.59万-453.33万-2230.92万 主力持仓 1、2025年4月23日公告：中红医疗秉持"在整合中创新，在学习中超越"的创新理念，不断推出高性能、 针对性的医疗产品以满足市场多元化需求。同时，借助数字化技术，将产品研发与数智升级有机结合， 开发出高品质、创新性的医用耗材与设备，实现医疗产品的智能化升级，致力于成为行业内领先的创新 型智惠医疗解决方案供应商。 2、公司主营业务产品以外销出口为主，并采取 ODM 直销方式，即公司实际为海外医疗器械及医疗耗 材等领域品牌商进行 ODM 生产，负责产品的自主设计与自主生产，品牌商提供外包装设计并以其自身 品牌在海外市场进行销售。 3、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席， ...

来源：新浪证券-红岸工作室 4、根据2024年年报，公司海外营收占比为81.56%，受益于人民币贬值。 5、公司属于国有企业。公司的最终控制人为厦门市人民政府国有资产监督管理委员会。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 2月26日，中红医疗跌1.84%，成交额4238.60万元，换手率0.84%，总市值54.98亿元。 异动分析 智能医疗+医疗器械概念+宠物经济+人民币贬值受益+国企改革 1、2025年4月23日公告：中红医疗秉持"在整合中创新，在学习中超越"的创新理念，不断推出高性能、 针对性的医疗产品以满足市场多元化需求。同时，借助数字化技术，将产品研发与数智升级有机结合， 开发出高品质、创新性的医用耗材与设备，实现医疗产品的智能化升级，致力于成为行业内领先的创新 型智惠医疗解决方案供应商。 2、公司主营业务产品以外销出口为主，并采取 ODM 直销方式，即公司实际为海外医疗器械及医疗耗 材等领域品牌商进行 ODM 生产，负责产品的自主设计与自主生产，品牌商提供外包装设计并以其自身 品牌在海外市场进行销售。 3、2025年3月3日官微：中红医疗亮相第1 ...

证券研究报告 | 首次覆盖报告 gszqdatemark 2026 02 24 年 月 日 行业：丁腈手套综合性能优异，需求持续景气。丁腈手套过敏率低，综合 性能表现优异，可应用于医疗、工业、民用等各类使用场景，渗透率持续 提升。据马来西亚丁腈手套龙头贺特佳，25 年全球橡胶手套需求约 3250- 3750 亿只，未来有望保持大单位数增长趋势。从供需结构来看，欧美需求 占比约 60%；供给则集中在中国和马来西亚，各占比 30%-40%。我们预 计在需求稳健增长、供给集中度提升的背景下，行业竞争将进一步回归成 本与效率。 核心壁垒：技术领先+原材料自供/燃煤优势+规模效应，成本优势突出。 丁腈手套行业竞争充分，成本优势为核心。公司通过技术、原材料、能源 及规模四个维度构筑难以复制的成本壁垒：① 产线新、自动化水平高， 生产效率持续领先；② 原材料与能源合计占成本约 6-7 成，其中公司核 心原材料丁腈胶乳自供比例达 80%，低于同业的外采依赖；同时公司为主 要全球手套厂商中少数以燃煤为主要能源结构的企业，较天然气或外购蒸 汽具备明显成本优势；③ 公司已成为全球最大的丁腈手套生产商，扩产 仍在推进，规模效应有望进 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5][9]. Core Insights - The company is a leading manufacturer of disposable gloves, particularly nitrile gloves, and has significantly expanded its production capacity from 19 billion units in 2019 to 56 billion units by mid-2025, establishing itself as a global leader in the nitrile glove market [1][15]. - The nitrile glove industry is experiencing robust demand due to its superior performance and low allergy rates, with global rubber glove demand projected to reach approximately 325 to 375 billion units by 2025, maintaining a strong growth trend [1][40]. - The company has built a strong cost advantage through technological leadership, self-supply of raw materials, and economies of scale, making it difficult for competitors to replicate its cost structure [2][47]. Company Overview - The company generates over 90% of its revenue from medical protective products, primarily nitrile and PVC gloves, with a significant portion of its sales coming from overseas markets, particularly North America and Europe [20][31]. - The management team is stable, with key executives having extensive experience in manufacturing, supply chain management, and international sales [27][30]. Industry Analysis - The nitrile glove market is characterized by a high-quality price ratio, with increasing penetration in various applications beyond medical use, driven by heightened public health awareness [31][36]. - The supply structure is dominated by manufacturers from Malaysia and China, with the demand primarily concentrated in the U.S. and Europe, which account for about 60% of global consumption [44][45]. Financial Projections - The company is expected to achieve revenues of 10.01 billion, 12.56 billion, and 14.48 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 5.15%, 25.41%, and 15.34% [11][9]. - The net profit forecast for the same period is projected to be 1.26 billion, 1.71 billion, and 2.19 billion yuan, reflecting growth rates of -14.1%, 36.2%, and 27.9% [11][9].

Core Viewpoint - Zhonghong Medical is focusing on innovation and digital technology integration to develop high-performance medical products, aiming to become a leading provider of intelligent medical solutions in the industry [2]. Group 1: Company Overview - Zhonghong Medical is primarily engaged in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, located in Tangshan, Hebei Province [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. - As of September 30, 2025, the company had a total market capitalization of 5.665 billion yuan [1]. Group 3: Market Position and Strategy - The company exports 81.56% of its revenue, benefiting from the depreciation of the RMB [4]. - Zhonghong Medical employs an ODM direct sales model, producing medical devices and consumables for overseas brand owners, who handle packaging and sales [2]. Group 4: Recent Developments - Zhonghong Medical showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical scenarios [3].

Core Viewpoint - Zhonghong Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Overview - Zhonghong Medical primarily focuses on ODM production for overseas medical devices and consumables, responsible for product design and manufacturing while brand owners handle packaging and sales [2]. - The company is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - Zhonghong Medical specializes in high-quality disposable protective gloves and medical consumables, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. - The company's overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Product Innovation and Market Presence - Zhonghong Medical showcased its innovative products at the 12th Beijing Pet Expo, including the Medrayna veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [3]. - The company aims to integrate digital technology into product development and smart upgrades, striving to become a leading provider of innovative medical solutions [2]. Group 4: Market Activity - The stock experienced a net inflow of 13.98 million yuan today, with a trading volume of 1.09 billion yuan and a turnover rate of 2.05% [1][6]. - The average trading cost of the stock is 14.22 yuan, with the current price near a support level of 13.54 yuan, indicating potential for price fluctuations [8].

Core Viewpoint - Zhonghong Medical is focusing on innovation and digital transformation in the medical device sector, with a significant portion of its revenue coming from overseas markets, benefiting from the depreciation of the RMB. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9] - The company was established on December 22, 2010, and went public on April 27, 2021 [9] - As of September 30, 2025, Zhonghong Medical had 22,400 shareholders, an increase of 11.24% from the previous period [10] Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38% [10] - The net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10] - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11] Group 3: Market Position and Strategy - The company primarily exports its products and operates under an ODM direct sales model, producing for overseas brand owners [2] - Zhonghong Medical is committed to integrating innovation and learning to develop high-performance medical products that meet diverse market needs [3] - The company is positioned as a state-owned enterprise, with its ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5] Group 4: Product Highlights - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [2] - The infusion pumps received positive feedback from veterinarians for their ease of use and adaptability to various clinical scenarios [2] Group 5: Market Trends - The company is part of the medical device industry, specifically in the medical consumables sector, and is influenced by trends in the pet economy, smart healthcare, and the depreciation of the RMB [2]

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Business Overview - Zhonghong Medical's main business includes the research, production, and sales of high-quality disposable protective gloves, with health protection products accounting for 89.48% of revenue, safety infusion products 6.22%, and innovative incubation products 4.30% [9]. - The company has a significant international presence, with 81.56% of its revenue coming from overseas markets, benefiting from the depreciation of the RMB [4]. Group 2: Product Innovation and Market Presence - The company showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [2]. - Zhonghong Medical emphasizes innovation through digital technology, aiming to develop high-quality, innovative medical consumables and equipment, positioning itself as a leading provider of intelligent medical solutions [3]. Group 3: Financial Performance - For the period from January to September 2025, Zhonghong Medical reported revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, while the net profit attributable to shareholders was a loss of 7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11].

Core Viewpoint - Zhonghong Medical is experiencing growth in its stock performance and is positioned to benefit from various market trends, including the pet economy and digital transformation in healthcare [1][2][4]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, Zhonghong Medical reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. Group 2: Market Position and Trends - The company primarily focuses on export sales, utilizing an ODM direct sales model, where it produces medical devices and consumables for overseas brand owners [2]. - Zhonghong Medical's overseas revenue accounted for 81.56% of its total revenue, benefiting from the depreciation of the Chinese yuan [4]. - The company is recognized as a state-owned enterprise, with its ultimate control held by the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal Government [5]. Group 3: Product Innovations and Developments - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical scenarios [2]. - The company emphasizes innovation through digital technology integration, aiming to develop high-quality, innovative medical consumables and equipment [3].

Core Viewpoint - 蓝帆医疗预计2025年将面临6.5亿至8.5亿元的亏损，但心脑血管事业部的强劲增长和健康防护事业部的毛利率回升为未来业绩改善提供了希望 [1] Group 1: Health Protection Business - 健康防护事业部的亏损扩大主要由于固定资产减值计提和中美经贸关系波动 [2] - PVC手套出口业务在中美经贸磋商后企稳，行业价格在2025年末回升，健康防护业务的毛利率在第四季度回正 [2] - 公司通过"减重"措施集中释放不利因素，为未来利润增长奠定基础 [2] Group 2: Cardiovascular Business - 心脑血管业务的扭亏证明了公司在高值耗材领域的竞争力，冠脉药物球囊在国家集采中的表现优异 [3] - 集采政策的转变为具备创新能力的企业带来长期利好，公司的创新管线储备决定了未来增长潜力 [3] - 公司在冠脉介入领域的多款创新产品获批，CE认证的冠脉血管内冲击波治疗系统为进入全球市场提供机会 [3] Group 3: Overall Outlook - 蓝帆医疗似乎已走出利空阶段，心脑血管业务的增长提供了安全垫，健康防护业务的周期触底提供了弹性空间 [3] - 公司有望迎来业绩与估值的双重提升 [3]